Miriam E. Tucker TOPLINE:European thyroid specialists report willingness to prescribe combination levothyroxine (LT4) + liothyronine (LT3) to patients with hypothyroidism who report persistent symptoms even after normalisation of thyroid-stimulating hormone (TSH) levels. These specialists report LT4+LT3 prescribing despite nearly half attributing patients’ persistent symptoms to nonendocrine causes, and the lack of evidence supporting the efficacy...
Category: <span>Clinical Practice</span>
Post
Lichen Sclerosus: The Silent Genital Health Concern Often Missed
954Ashley Winter, MD, remembers the first time she Googled the skin condition lichen sclerosus. Most of the websites listed the autoimmune condition as a rare disease. In the realm of genital health, some conditions remain shrouded in silence and consequently are more likely to go undercounted and underdiagnosed, Winter, a urologist based in Los Angeles,...
Post
Don’t Be Misled: Proper Dermatology Diagnoses Crucial for Accurate Treatment
Perioral dermatitis can look a lot like atopic dermatitis. For primary care clinicians, the similarity in presentation can create challenges in providing the right treatment and knowing when a patient needs to be referred to a dermatologist. The two conditions look similar; both present with itchy, swollen rashes. But atopic dermatitis can be located anywhere...
Post
Lebrikizumab Found Effective for Patients With Eczema, Darker Skin Tones
SAN DIEGO — Among patients with skin of color and moderate to severe atopic dermatitis (AD) who underwent 16 weeks of treatment with lebrikizumab, 68% achieved a 75% reduction in the Eczema Area and Severity Index (EASI-75), interim results from a novel phase 3b trial showed. Lebrikizumab, a novel monoclonal antibody being developed by Eli...
Post
Veterans with Blast Injuries Show Spinal Fluid Changes Similar to Alzheimer’s
Veterans with traumatic brain injuries show spinal fluid alterations resembling those in Alzheimer’s patients. University of Washington School of Medicine Credit: Benjamin Faust / Unsplash. U.S. veterans of the wars in Afghanistan and Iraq who suffered mild traumatic brain injury from exposure to explosive blasts were found to have changes in cerebrospinal fluid proteins that...
Post
Aging population to be major driver of future climate-related deaths, predicts study
by Jane E. Dee, Yale University Climate change poses profound public health threats to people of all ages. But as the climate changes, the world is facing another public health challenge: aging. The proportion of the world’s population 65 and older is projected to rise from 9% at present to 16% in 2050. As the...
Post
Tirzepatide found to reduce body weight, waist circumference in those with obesity regardless of duration of condition
by European Association for the Study of Obesity Credit: CC0 Public DomainNew research to be presented at this year’s European Congress on Obesity (Venice, Italy, May 12-15) shows that the obesity medication tirzepatide consistently reduces body weight and waist circumference regardless of the length of time the person has been living with overweight or obesity....
Post
Clinical study of a blood test shows 83% accuracy for detecting colorectal cancer
by Fred Hutchinson Cancer Center Credit: CC0 Public DomainA blood test intended for screening for colorectal cancer in people who are of average risk and not experiencing symptoms correctly detected colorectal cancer in 83% of people confirmed to have the disease, according to a study published March 14 in the New England Journal of Medicine....
Post
Next-generation stool DNA test found to have best detection rate of noninvasive colorectal cancer screening tools
by Regenstrief Institute Credit: Pixabay/CC0 Public DomainA study of more than 21,000 average risk patients at 186 sites across the U.S., led by Regenstrief Institute and Indiana University School of Medicine research scientist Thomas Imperiale, M.D., has found that the next-generation multi-target stool DNA colorectal cancer screening test detects 94% of colorectal cancers. This test...
Post
FDA approves Madrigal’s NASH drug, marking the first-ever treatment for the liver disease
FDA approves Madrigal’s NASH drug, marking the first-ever treatment for the liver diseaseNicole DeFeudisEditorMadrigal Pharmaceuticals’ NASH drug won an accelerated approval on Thursday, becoming the first treatment for a liver disease that for years has vexed scientists and investors. The medication, resmetirom, was approved under the brand name Rezdiffra for patients with stage 2 and...